HIRUNDO
LIVE

Serial Number

79421230

Owner

B.C.I. Pharma

Attorney

Rebecca Liebowitz

Filing Date

Dec 2, 2024

Add to watchlist:

No watchlists yet
View on USPTO

HIRUNDO Trademark

Serial Number: 79421230 • Registration: 8182268

HIRUNDO is a trademark filed by B.C.I. Pharma on December 2, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

B.C.I. Pharma

Avenue de l’Hôpital 11

Entity Type: 98

Daphne Vervaet

Hoogstraat 49

Entity Type: 98

Hirundo Biosciences

Boulevard de Patience et Beaujonc 3

Entity Type: 98

Trademark Details

Filing Date

December 2, 2024

Registration Date

March 24, 2026

Published for Opposition

January 27, 2026

Goods & Services

Pharmaceutical preparations and substances in the field of gynecology and women's health, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; medicinal preparations for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; medicines for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; biochemical medicines for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; pharmaceutical preparations for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, Inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions for use in the field of gynecology and female health; estrogen preparations for therapeutic purposes; pharmaceutical preparations containing estrogen for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; pharmaceutical preparations for the treatment of female hormonal dysfunction; pharmaceutical preparations for use in hormone replacement therapy; pharmaceutical preparations for the treatment of menopausal symptoms, conditions and disorders

Chemicals for industrial purposes and chemical preparations for scientific purposes; chemical reagents for scientific purposes in the field of molecular biology; bacterial preparations other than for medical or veterinary use; enzymes and enzyme preparations for industrial use; chemical preparations for analyses in laboratories for scientific use, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes, for use in the research and development and production of drugs, medicinal and pharmaceutical preparations; chemical additives for use in the manufacturing of pharmaceuticals

Medical services; providing medical advice in the field of efficacy of pharmaceuticals; provision of medical data relating to the use of pharmaceuticals; medical information online and on the internet relating to products, solutions and pharmaceutical and medical advances; medical information online and on the internet about products, solutions, pharmaceutical or medical advances; providing medical research information in the field of pharmaceuticals

Market research and business analysis services; business marketing consulting services in the field of pharmaceutical, biotechnology, biochemical, medical device and diagnostics industries; market analysis; providing business information and data processing services in the field of pharmaceutical, biotechnology, biochemical medical device, and diagnostics industries; compilation of statistics for business or commercial purposes in the field of biochemical medical devices

Scientific, clinical surgery, medical and life-science research; research and development in the field of biotechnology and biochemistry; research and development in the field of pharmaceuticals, biopharmaceuticals, medical devices, and medical diagnostics; research relating to molecular sciences; research and development in the field of drug development; testing, analysis, and evaluation of pharmaceutical and biochemical products, especially for use in medicines; research and development of medicines; testing of pharmaceuticals; biotechnology research and development services; product development involving pharmaceutical products; medical and scientific research, namely, conducting clinical trials as part of the research and development of pharmaceuticals and medicines; clinical research in the field of production of chemicals for pharmaceutical use, pharmaceuticals, medical devices and medical diagnostics; scientific research, namely, providing analysis of statistical data in the field of biotechnology; scientific research, namely, providing analysis of statistical data in the field of biotechnological diagnostics industries

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 24, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 24, 2026 R.PR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 27, 2026 ERRR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 26, 2026 ADCH
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 27, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jan 27, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 21, 2026 NONP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 2, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 2, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 2, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 2, 2026 REAP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 2, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 2, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 2, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 2, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 2, 2026 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 2, 2026 GNFN
FINAL REFUSAL E-MAILED
Jan 2, 2026 GNFR
FINAL REFUSAL WRITTEN
Jan 2, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 30, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 30, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 30, 2025 TROA
REFUSAL PROCESSED BY IB
Aug 2, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 14, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 14, 2025 RFRR
CHANGE OF OWNER RECEIVED FROM IB
May 30, 2025 CHLD
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 22, 2025 RFCR
NON-FINAL ACTION WRITTEN
May 21, 2025 CNRT
ASSIGNED TO EXAMINER
May 21, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 11, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 11, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 10, 2025 REPR